Blends
CJC-1295 no DAC / Ipamorelin
What is it?
This is the two-component entry for which the attachment specifies a ratio: 5 mg of the no-DAC CJC-labelled material and 5 mg of ipamorelin, for 10 mg total. Both names concern growth-hormone research, but they target different receptor systems.
How it is studied
The proposed combination pairs GHRH-related signalling with a ghrelin-receptor secretagogue. Physiological interaction between pathways does not establish a predictable or desirable result for a premixed product. Sequence, formulation and mixture stability are separate questions.
What the evidence shows
Ipamorelin has preclinical and early human pharmacology data. The well-known CJC-1295 clinical paper studied the DAC-containing form, so it is not direct evidence for the no-DAC component of this blend. Neither source validates the CP10 formulation as a whole.
Limitations & safety context
The stated component masses are useful specification details but do not verify the exact CJC sequence or the purity of either peptide. A combined endocrine response is not proof of improved sleep, body composition or recovery. Blend-specific safety and stability evidence are not provided.
Listed specifications
| Reference | Listed contents |
|---|---|
| CP10 | 5 mg no-DAC CJC + 5 mg ipamorelin |
Source-document quantities, not doses or a confirmation of stock. Identity, purity, component composition and suitability require separate documentation.
Research information only. No dosing, administration or treatment advice.